Investor Day 2011

Investor Day MONDAY, OCTOBER 17

Milan

DISCLAIMER Save where otherwise indicated, the Company is the source of the content of this Presentation. Care has been taken to ensure that the facts stated in this Presentation are accurate, and that the opinions expressed are fair and reasonable.

However, no representation or warranty, express or implied, is made or given by or on behalf of the Company, or the management or employees of Company as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation. None of the Company, shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this Presentation or its contents or otherwise arising in connection therewith.

This Presentation is not intended for potential investors and does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or solicitation of any offer to purchase or subscribe for, any securities of the Company, nor should it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute a recommendation regarding the securities of the Company.

This Presentation contains various forward-looking statements that reflect the Company’s management’s current views with respect to future events and financial and operational performance. The words “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “should”, “could”, “aim”, “target”, “might”, or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company’s control and may cause actual results or performance to differ materially from those expressed or implied from such forward-looking statements. These risks include, but are not limited to, the Company’s ability to, operate profitably, maintain its competitive position, the Company’s ability to promote and improve its reputation and the awareness of the brands in its portfolio, the Company’s ability to operate its growth strategy successfully, the impact of changes in pricing policies, political and regulatory developments in the markets in which the Company operates, and other risks.

OPENING REMARKS Gustavo Denegri Chairman Carlo Rosa Chief Executive Officer

DIASORIN: RIDING A NEW BUSINESS WAVE • COMPANY PROPOSITION AS A SPECIALTY PLAYER IN THE DIAGNOSTIC BUSINESS

• NEW R&D PIPELINE IN BOTH LARGE CONSOLIDATED MARKETS (e.g. IDs) OR MID-SIZE SPECIALTY CLINICAL AREAS (e.g. GI INFECTIONS, CKD)

• TECHNOLOGICAL SHIFT FROM ELISA TO CLIA LEVERAGING ON AVAILABLE KNOW HOW AND MATERIAL

• MOLECULAR PRODUCTS TO COMPLEMENT AND SUPPORT IMMUNOASSAY OFFERING

• WORLDWIDE GEOGRAPHICAL EXPANSION • KEY M&A ACQUISITIONS TO PROVIDE MORE SPECIALTY PRODUCTS OR BRAND RECOGNITION

• MANAGING VITAMIN D LEADERSHIP POSITION

2012-2015

2000-2011

• LEADERSHIP POSITION IN VITAMIN D TESTING

• FURTHER GEOGRAPHICAL EXPANSION

DIASORIN CONTINUING TO GENERATE REVENUE GROWTH, CASH GENERATION AND A STRONG BALANCE SHEET

DIASORIN HISTORY 1968

DiaSorin’s birth as division of Sorin Biomedica SpA

1970-1985

Development of products portfolio with RIA and ELISA technologies

1986-1999

2000-2006

Acquisition of Byk Sangtec and rights to LIAISON® platform Start of conversion from ELISA to CLIA technology Commercial presence strengthened (new branches in Mexico, Israel and China) R&D focused on Liaison® products portfolio expansion: i) families of reagents and ii) “specialty” reagents

Investment in Molecular Diagnostics: licensing agreement with Eiken Chemical Co. Ltd. for use of LAMP technology Worldwide expansion and consolidation (Portugal, Austria, Czech Republic, Canada, Australia, Ireland, South Africa, Netherlands) Acquisition of Biotrin, strengthening leadership position as “specialist” in IVD market Acquisition of Murex® product line, entering blood bank market Launch of new Liaison® XL system platform DiaSorin promoted to Italian Stock Exchange Index “FTSE MIB”

Today

Liaison® XL meeting needs of large laboratories, and consolidating/expanding DiaSorin commercial presence Murex® product line, playing an important role in blood-bank market Development of new technologies (Molecular Diagnostics) to renew current product line Product line expansion, focusing on specialized segments: Infectious and Autoimmune Diseases, Endocrinology

HISTORY OF GROWTH AND VALUE AS DIAGNOSTIC SPECIALIST, BASED ON CONTINUOUS INNOVATION, TOP-QUALITY PRODUCTS AND LONG-STANDING COMMITMENT TO THE CLIENTS NEEDS

EXTERNAL ACQUISITIONS

2007-2010

STRONG FINANCIAL PERFORMANCE

July 19, 2007: Stock market debut in the Italian Stock Exchange “STAR” segment

COMMERCIAL EXPANSION WORLDWIDE

2007

BIOCHEMISTRY INTEGRATED WITH AUTOMATED MACHINES

Management Buyout, backed by Investimenti e Partecipazioni SpA and other financial and industrial investors

MANAGEMENT CONVICTION AND COMMITMENT TO RESULTS

2000

TECHNOLOGICAL DEVELOPMENT AND PRODUCTS MENU EXPANSION

Sorin Biomedica acquires control of Incstar Inc. (US company in the In Vitro Diagnostics market), divests IVD activities in a separate company “DiaSorin Srl”, and sells it to American Standard Inc.

DIASORIN WORLDWIDE PRESENCE

28 1,500 EMPLOYEES

INDUSTRIAL SITES

6

RESEARCH FACILITIES

2 >80

SALUGGIA, GERENZANO* DUBLIN DARTFORD DIETZENBACH

AUSTRIA BENELUX CZECH REPUBLIC FRANCE FINLAND GERMANY IRELAND

AMERICAS

USA

STILLWATER

BRAZIL CANADA

SOUTH AFRICA

KYALAMI

ITALY IRELAND UK GERMANY * RESEARCH CENTER

APAC

COMPANIES WORLDWIDE

SUBSIDIARIES

AFRICA

EUROPE AND MIDDLE EAST

INDUSTRIAL SITES

ISRAEL ITALY PORTUGAL SPAIN SWEDEN NORWAY UK

DISTRIBUTORS BOSNIA AND HERZEGOVINA CROATIA CYPRUS DENMARK ESTONIA GREECE HUNGARY JORDAN KUWAIT LATVIA LEBANON

LITHUANIA POLAND ROMANIA RUSSIAN FEDERATION SAUDI ARABIA SLOVAKIA SLOVENIA SWITZERLAND TURKEY UNITED ARAB EMIRATES UKRAINE YUGOSLAVIA

ARGENTINA BOLIVIA CHILE COLOMBIA COSTA RICA DOMINICAN REPUBLIC ECUADOR HAITI

HONDURAS MEXICO PANAMA PARAGUAY PERU PUERTO RICO URUGUAY VENEZUELA

SOUTH AFRICA

ALGERIA EGYPT

TUNISIA

CHINA AUSTRALIA

BANGLADESH INDIA INDONESIA JAPAN KOREA REPUBLIC MALAYSIA MONGOLIA

PAKISTAN PHILIPPINES SINGAPORE TAIWAN THAILAND VIETNAM

MEXICO USA

INDEPENDENT DISTRIBUTORS GROUP PRESENCE IN

>60 COUNTRIES

MARKETS ADDRESSED DIRECTLY AND THROUGH LONG-TERM CONTRACTS WITH MAJOR DISTRIBUTORS

IN VITRO DIAGNOSTIC (IVD) MARKET EACH SEGMENT OF THE IVD MARKET DIFFERS FOR: • Assay technology • Assay automation • Personnel responsibility • Regulatory complexity • Location of the lab in the hospital

CLINICAL CHEMISTRY 21%

IMMUNOASSAY

General markers (Enzymes, electrolytes, etc)

Infectious immunology Hepatitis and HIV testing Immunochemistry All sort of viral disease testing

MICROBIOLOGY Testing for live microrganisms (bacteria, protozoa, etc)

23% 6% 6% 6%

21%

SELF-MONITORING BLOOD GLUCOSE OTHERS

9% 9%

MOLECULAR DIAGNOSTICS Testing for genetic disorders

POINT OF CARE HEMATOLOGY

Includes all blood cells testing

MARKET REQUIRING HIGH LEVEL OF SPECIALTY IN EACH SEGMENT, IMPLYING A BIG MARKET FRAGMENTATION

IMMUNOASSAY CLINICAL AREAS DIASORIN AIMS TO PLAY AN IMPORTANT ROLE IN A € 7BN MARKET AS AT 2010 BY COMBINING A DIFFERENT STRATEGY APPROACH FOR EVERY CLINICAL AREA IN THE IMMUNOASSAY MARKET

AUTOIMMUNITY BONE & MINERAL

ALLERGY 9.3%

INFECTIOUS DISEASE

GI STOOL TESTING

6.4% 5.7% 4.3%

12.1%

DRUG MONITORING & OTHERS

3.6%

CARDIAC MARKERS 12.9%

25.7%

ONCOLOGY & ENDOCRINOLOGY

20.0%

HEPATITIS AND RETROVAIRUSES

DIASORIN READY TO INCREASE ITS OFFERING AND COMPETITIVE POSITION IN THE IMMUNOASSAY MARKET

IN VITRO DIAGNOSTIC (IVD) MARKET IVD TESTS ARE MEDICAL DEVICES, PERFORMING DIAGNOSES FROM ASSAYS IN A TEST TUBE, OR IN A CONTROLLED ENVIRONMENT OUTSIDE A LIVING ORGANISM REAGENTS INSTRUMENTS CONTROLS

BLOOD EXAMINING SPECIMENS

TISSUES

PHYSIOLOGICAL/PATHOLOGICAL STATE SAFETY BLOOD SUPPLY

PROVIDING INFORMATION ON

COMPATIBILITY BETWEEN DONOR/RECIPIENT

STOOL AND URINE

GENETIC TESTING THERAPEUTIC TREATMENT

END-USERS

PRODUCT USES

HOSPITAL LABORATORY

CLINICAL DIAGNOSTIC

BLOOD BANKS

CENTRALIZED DIAGNOSTICS

COMMERCIAL ANALYSIS LABORATORY

MOLECULAR DIAGNOSTICS AND GENETICS

RESEARCH PHARMA INDUSTRY

BASIC RESEARCH

RESEARCH LABORATORY

SPECIALIZED CLINIC

PATIENTS IVD MARKET: PURPOSES & END-USERS

MASS CONSUMPTION

SELF TESTING

PHYSICIANS

GROWTH POTENTIAL FOR IVD MARKET

DEMOGRAPHICS

Ageing population drives increased diagnostics demand Prevalence and incidence increase of certain diseases

FOCUS ON PREVENTION AND DIAGNOSIS

Increasing focus by government and other third party payers on diagnostic testing as a mean to decrease healthcare costs, given clear cost benefits

EVIDENCE BASED MEDICINE

Increased focus by physicians on evidence based medicine, due to cost and potential side-effects of many treatments

EMERGING MARKETS GROWTH

Higher lifestyle standards drive a higher demand of diagnostics in emerging markets and represent an hedge against economic weakness in mature markets

IVD: SUSTAINABLE GROWTH IN A VALUE MARKET

IMMUNOASSAY TECHNOLOGIES

FEATURES TRACER TECHNOLOGY

AUTOMATION LEVEL OF INTERVENTION REQUIRED

EVIDENCE

TECHNOLOGY BASED FLEXIBILITY

MEDICINE

TIME TO 1ST RESULT TEST FORMAT

RIA

ELISA

CLIA

RADIO IMMUNO ASSAY

ENZYME LINKED IMMUNOSORBENT ASSAY

CHEMILUMINESCENT IMMUNO ASSAY

RADIOACTIVE

NON-RADIOACTIVE COLORIMETRIC

LUMINESCENT MOLECULAR

N/A

BATCH PLATE ANALYZERS

CLOSED/DEDICATED ANALYZERS

MANUAL OPERATION BY EXPERT TECHNICIANS

SIGNIFICANT INTERVENTION BY QUALIFIED LABORATORY PERSONNEL

INTERVENTION LIMITED TO LOAD KITS

TESTS THAT CANNOT BE CARRIED OUT USING MORE MODERN TECHNOLOGIES

OPEN SYSTEM ELISA KITS FROM DIFFERENT PRODUCERS CAN BE USED ON THE SAME ANALYZER

CLOSED SYSTEM

3-12 HOURS

3-4 HOURS

30 MINUTES

BATCH

BATCH

RANDOM ACCESS

DIASORIN MANAGING ALL DIFFERENT IMMUNOASSAY TECHNOLOGIES

M&A TARGET

2002

BYK SANGTEC (IVD BUSINESS DIVISION)

SELLER

ALTANA AG

STRATEGY AND INVESTMENT RATIONALE

RIGHTS TO LIAISON® PLATFORM INTEGRATION BETWEEN BIOCHEMISTRY AND AUTOMATIZATION

EFFECTS ON BUSINESS

COMMERCIAL EXPANSION

TECHNOLOGICAL AREA

CLIA

PRODUCTS MENU EXPANSION COMPANY BRAND ENHANCEMENT

2003

2008

MOLECULAR DIAGNOSTICS (MDX)

GAMIDA SENSE LTD.

ASSET IN MOLECULAR DIAGNOSTICS

KNOW-HOW

NUCLEIC ACID TESTING (NAT)

BIOTRIN INTERNATIONAL LTD

DR SCHMIDT BIOTECH GMBH

LEADERSHIP POSITION STRENGTHENING AS A “SPECIALIST” IN IVD MARKET NEW GEOGRAPHICAL AREAS

CRITICAL MASS IN STRATEGIC AREAS (APAC & LATAM)

ELISA

MUREX PRODUCT LINE

ABBOTT LABORATORIES LTD

MUREX® PRODUCT LINE SUPPORTING LIAISON XL LAUNCH ENTRANCE IN BLOOD BANK MARKET THROUGH MUREX KNOW-HOW AND REPUTATION IN HCV-HIV SEGMENT

DIASORIN BECOMING 2ND MAIN MANUFACTURER OF ELISA IN THE WORLD MUREX SALES IN LATAM & APAC INCREASING DIASORIN CRIMCAL MASS IN UNDERPENETRATED AREAS

ELISA CLIA

2010

Technologies

Menu Expansion

COMPANY’S GROWTH GRANTED BY KEY ACQUISITIONS

CLIA

PARTNERSHIPS TARGET

PARTNER

STRATEGY AND INVESTMENT RATIONALE

EFFECTS ON BUSINESS

TECHNOLOGICAL AREA

LIAISON XL

STRATEC BIOMEDICAL SYSTEMS AG

DEVELOPMENT OF NEW FRONT-LINE INSTRUMENT: LIAISON XL

CLIENTS BASE ENLARGEMENT

CLIA

LAMP TECHNOLOGY

EIKEN CHEMICAL CO. LTD.

INVESTMENT IN MOALECULAR DIAGNOSTICS: LICENSING AGREEMENT FOR USE OF LAMP TECHNOLOGY

LICENSING AGREEMENT

NUCLEIC ACID TESTING (NAT)

LIAISON IAM

PRECISION SYSTEM SCIENCE CO. LTD (PSS)

DEVELOPMENT OF NAT ANALYZER (LIAISON IAM) TO ENTER MOLECULAR DIAGNOSTICS MARKET MARKET SYNERGIES WITH BIOTRIN BUSINESS

COMPANY BRAND AND PRODUCTS ENHANCEMENT IN SPECIALTY CLINICAL AREAS

NUCLEIC ACID TESTING (NAT)

HBsAg

ADVANCED LIFE SCIENCE INSTITUTE INC. (ALSI)

DEVELOPMENT OF NEW HIGHLY SENSITIVE TEST FOR HEPATITIS B VIRUS POSITIONING AS “SPECIALIST” IN INFECTIOUS DISEASES AREA

DEVELOPMENT AND LICENSING AGREEMENT

CLIA

2011

WORLDWIDE DISTRIBUTION

SONIC HEALTHCARE GROUP

LONG-TERM WORLDWIDE INCENTIVE AGREEMENT TO USAGE OF DIASORIN PRODUCTS IN SONIC HEALTHCARE LABORATORIES

LICENSING AGREEMENT GEOGRAPHICAL EXPANSION COMPANY BRAND AND STABILITY ENHANCEMENT

CLIA

2011

VITAMIN D LIAISON XL

LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)

US NETWORK STABILITY INCREASE GROWTH AND BRAND AWARENESS IN LARGE COMMERCIAL LABORATORIES

5 YEAR SUPPLY AGREEMENT GROWTH IN THE US MARKET

CLIA

VITAMIN D

CARDINAL HEALTH INC.

US NETWORK STABILITY INCREASE GROWTH AND BRAND AWARENESS IN LARGE COMMERCIAL LABORATORIES

EXCLUSIVE DISTRIBUTION AGREEMENT GROWTH IN THE US MARKET

ELISA

2005

2011

2011

2008

2011 Technologies

LIAISON XL

Menu Expansion

CLIA

Commercial Partnerships

COMPANY’S GROWTH GRANTED BY A COMBINATION OF INTERNAL R&D AND COMMERCIAL/LICENSING AGREEMENTS

R&D AND INNOVATION Francesco Colotta Senior Corporate VP and Chief Medical Officer

IN VITRO DIAGNOSTICS: BASICS

IN VITRO DIAGNOSTICS

DETECTION IN BIOLOGICAL FLUIDS...

...OF A “MOLECULE”...

...“RELATED” TO A DISEASE

E.G.

BLOOD, URINE, CSF,…

E.G.

PROTEINS

NUCLEIC ACIDS

SMALL MOLECULES

IMMUNODIAGNOSTICS

MOLECULAR DIAGNOSTICS

CLINICAL CHEMISTRY

DETECTION BY ANTIBODIES…

DETECTION BY DNA…

…BY A LIGHT-EMITTING MOLECULE

…BY A FLUORESCENCE-EMITTING MOLECULE

DETECTION BY CHEMICAL REACTIONS

INFECTIOUS DISEASES

INFECTIOUS DISEASES

ELECTROLYTES

ONCOLOGY

ONCOLOGY

GLUCOSE

HORMONOLOGY

OTHERS

CHOLESTEROL

AUTOIMMUNITY

HEPATIC ENZYMES

CARDIOLOGY

OTHERS

FERTILITY THYROID THE BASICS OF DIASORIN MARKET

AREAS TO BE A FRONT RUNNER IN LAB TESTING • STRENGTHEN OUR LEADERSHIP IN IMMUNOASSAY • BECOME A NEW PLAYER IN MOLECULAR DIAGNOSTIC

IMMUNODIAGNOSTICS

MOLECULAR DIAGNOSTICS

DETECTION BY ANTIBODIES…

DETECTION BY DNA…

…BY A LIGHT-EMITTING MOLECULE

…BY A FLUORESCENCE-EMITTING MOLECULE BLOOD BANKS INFECTIOUS DISEASES

INFECTIOUS DISEASES

INFECTIOUS DISEASES SPECIALTIES

GI TRACT ONCOLOGY

ONCOLOGY HYPERTENSION

ONCO-HEMATOLOGY SPECIALTIES

HORMONOLOGY CHRONIC KIDNEY DISEASE

OTHERS

AUTOIMMUNITY CARDIOLOGY FERTILITY THYROID

R&D STRATEGY BASED ON 2 LEGS: LEADERSHIP ON IMMUNOASSAY + MOLECULAR DIAGNOSTIC ENTRANCE

BLOOD BANKS DEVELOPMENT PROGRAM LEVERAGE DIASORIN EXPERIENCE AND REPUTATION IN IDS

LEVERAGE DIASORIN FULL MENU AVAILABILITY T. pallidum HBsAg

HTLV I-II

HCV

Chagas

HIV

HIV HT

LIAISON XL

In development DIASORIN LEVERAGING EXPERIENCE, REPUTATION, FULL MENU AVAILABILITY, LIAISON XL

BLOOD BANKS

NEW AUTOMATED SYSTEM IN STOOL TESTING SET UP OF OPTIMAL ASSAY CONDITIONS WITH LIAISON AND LIAISON XL

COMPANION ONE-STEP SIMPLE SAMPLE PREPARATION DEVICE

GI INFECTIONS C. DIFFICILE TOXINS A&B

ENTEROHEMORRAGIC E. COLI

C. DIFFICILE GDH

ROTAVIRUS

H. PYLORI

ADENOVIRUS

GI INFLAMMATORY/AUTOIMMUNE DISEASES CALPROTECTIN LACTOFERRIN LIPASE

FECAL OCCULT BLOOD

LIAISON 庐 STOOL CLEAN-UP DEVICE

DEVELOP AN INNOVATIVE IMMUNODIAGNOSTIC CHEMILUMINESCENT SYSTEM CHARACTERIZED BY: 路 BIOLOGICAL MATRIX CURRENTLY POORLY AUTOMATED 路 WIDE APPLICABILITY 路 INTEGRABLE WITH MOLECULAR DIAGNOSTICS A NEW AUTOMATED SYSTEM IN STOOL TESTING; DIASORIN DRIVING THE MARKET

LEVERAGE ON BONE METABOLISM FRANCHISE CHRONIC KIDNEY DISEASE (CKD) AND BONE METABOLISM CKD

BONE MASS LOSS

HIGH BONE TURNOVER (INCREASED REABSORPTION)

LOW BONE TURNOVER (REDUCED FORMATION)

HYPERPHOSPHATEMIA

FGF-23

HYPERPHOSPHATEMIA

FGF-23

REDUCED 1,25 VITD

1,25 VITD SPECIFIC ASSAY

REDUCED 1,25 VITD

1,25 VITD SPECIFIC ASSAY

HIGH SCLEROSTIN

SCLEROSTIN ASSAY

ENLARGEMENT OF BONE METABOLISM FRANCHISE

HYPERTENSION: A FULL PANEL ON LIAISON SYSTEMS DIASORIN MENU: A UNIQUE OFFER FOR THE DETECTION OF THE KEY HYPERTENSION MARKERS ON A FULLY AUTOMATED PLATFORM DIFFERENT “TYPES” OF HYPERTENSION RENOVASCULAR HYPERTENSION RENIN-SECRETING TUMORS HIGH RENIN ESSENTIAL HYPERTENSION LOW RENIN ESSENTIAL HYPERTENSION PHEOCHROMOCYTOMA PRIMARY ALDOSTERONISM DRUGS-INDUCED HYPERTENSION

Renin and aldosterone are differentially expressed in each specific hypertension-inducing condition

To discriminate which h clinical l l condition is inducing hypertension in the patient, both RENIN and ALDOSTERONE must be measured UNIQUE OFFER OF AUTOMATED DETECTION OF THE TWO KEY MARKERS OF HYPERTENSION ON LIAISON

DIASORIN IN THE MOLECULAR DIAGNOSTICS

DIASORIN STRATEGY TO PLAY THE MOLECULAR DIAGNOSTIC MARKET

THE 3 KEY DECISIONS

AMPLIFICATION TECHNOLOGY

LAMP

AUTOMATED NA AMPLIFICATION AND DETECTION INSTRUMENT

NAT MENU

LIAISON IAM

INFECTIOUS DISEASES AND ONCOHEMATOLOGY TESTS

3 DECISIONS, 1 WINNING STRATEGY IN MOLECULAR DIAGNOSTICS

LAMP TO DEVELOP A SPECIALTY MENU IN NAT DIASORIN LICENSED LAMP (LOOP-MEDIATED ISOTHERMAL AMPLIFICATION) TECHNOLOGY FROM EIKEN CHEMICAL COMPANY LTD IN 2008: THE DIFFERENTIATION FACTOR IN ONCO-HEMATOLOGY FUTURE MENU

DIASORIN LAMP grants: HIGHER SENSITIVITY HIGHER SPECIFICITY SIMPLER REACTION SET-UP SHORTER TIME-TO-RESULT CHEAPER PRICE

LAMP: THE DIFFERENTIATION FACTOR IN THE DIASORIN MOLECULAR DIAGNOSTIC STRATEGY

LIAISON IAM: A SMALL AUTOMATED ANALYZER DIASORIN SIGNED AN AGREEMENT WITH PRECISION SYSTEM SCIENCE CO. LTD OF JAPAN (PSS) FOR THE DEVELOPMENT OF A NUCLEIC ACID TEST (NAT) ANALYZER

CLIENTS S

DIASORIN MICROBIOLOGY CUSTOMERS DIASORIN SPECIALITIES SEROLOGY CUSTOMERS CUSTOMERS ALREADY USING VALIDATED EXTRACTION METHOD

FEATURES

Liaison Instant Amplification Molecular (IAM)

• SMALL: BENCH TOP, 150(w) X 300(h) X 300(d), <6kg • FAST: REAL TIME; ONE RUN <60MIN. • PRECISE: FLUORESCENCE QUANTITATION • FLEXIBLE: • THROUGHPUT: FROM 1 TO 8 REACTIONS/INSTRUMENT; UP TO 48 REACTIONS (WITH 6 INSTRUMENTS) • RANDOM ACCESS: BY USING DIFFERENT INSTRUMENTS • MULTIPLEX CAPABILITY: 3 FLUORESCENT DYES • DIFFERENT ASSAYS CAN BE PERFORMED IN THE SAME RUN • FULL TRACEABILITY: BAR CODE READER USE FOR SAMPLER AND REAGENTS • CONNECTIVITY: TO LIS • CLOSED SYSTEM: FOR ONLY ISOTHERMAL LAMP REACTION • LOW RISK OF CONTAMINATION: PLASTIC STRIP CAN’T BE RE-OPENED AFTER CLOSURE • EASY TO USE: INTUITIVE SOFTWARE

DIASORIN DEVELOPING ITS NAT ANALYZER, FOCUSED ON SPECIALTY TESTS

NAT MENU: FOCUS ON SPECIALTIES

LEVERAGE DIASORIN EXPERIENCE AND REPUTATION IN INFECTIOUS DISEASES

PROVIDE THE SPECIALIST WITH A COMPLETE PANEL

INFECTIOUS DISEASES SPECIALTIES

ONCO-HEMATOLOGY SPECIALTIES

EPSTEIN–BARR VIRUS (EBV)

MYELOPROLIFERATIVE NEOPLASMS (MYELO NEOPL)

CYTOMEGALOVIRUS (CMV)

ACUTE LYMPHOBLASTIC LEUKEMIAM (ALL)

PARVOVIRUS (PARVO)

ACUTE MYELOID LEUKEMIA (AML)

TOXOPLASMOSIS (TOXO)

ACUTE PROMYELOCITIC LEUKEMIA (APL)

BK VIRUS (BKV)

CHRONIC MYELOID LEUKEMIA (CML)

VARICELLA ZOSTER VIRUS (VZV)

DIASORIN MOLECULAR DIAGNOSTICS MENU: CONTENT IS ALWAYS THE KEY DRIVER IN OUR BUSINESS

LAS CONFIGURATION AND LIAISON XL LAS BRINGS LIAISON XL INTO THE MOST ADVANCED, HIGH THROUGHPUT AND AUTOMATED DIAGNOSTIC LABS, TO FULFILL FLEXIBILITY AND EFFICIENCY OF THE NEW ANALYZER

DEVELOPMENT PLAN: • UPGRADE SW AND HW TO INTEGRATE LIAISON XL INTO AUTOMATED PATIENT SAMPLE PROCESSING: LABORATORY AUTOMATION SYSTEM (LAS) • PROTOTYPE SW AND HW READY LIAISON XL READY FOR LAS CONFIGURATION

DIASORIN: R&D PIPELINE 2011 - 2015 LEVERAGE DIASORIN EXPERIENCE AND REPUTATION IN IDS

INFECTIOUS DISEASES

DEVELOP AN INNOVATIVE IMMUNODIAGNOSTIC CHEMILUMINESCENT PLATFORM CHARACTERIZED BY: 路 BIOLOGICAL MATRIX CURRENTLY POORLY AUTOMATED 路 WIDE APPLICABILITY 路 INTEGRABLE WITH MOLECULAR DIAGNOSTICS

IMMUNOASSAY

EXPLOIT DIASORIN WORLD LEADERSHIP IN VIT D TESTING AND BONE METABOLISM

BLOOD BANK K HTLV I-II

CHAGAS

HIV - HT

AUTOMATED STOOL TESTING C. DIFFICILE ROTAVIRUS

H. PYLORI ADENOVIRUS ADENO OVIRUS O V

CALPROTECTIN LACTOFERRIN

ENTER E. COLI LIPASE

FECAL OCCULT BLOOD

BONE O & MINERAL FGF-23

1,25 VITD

SCLEROSTIN

HORMONOLOGY HYPERTENSION N

UNIQUE OFFER TO DETECT KEY HYPERTENSION MARKERS ON FULLY AUTOMATED PLATFORM

ALDOSTERONE

INFECTIOUS DISEASES MOLECULAR DIAGNOSTICS

LAMP ANALYZER

FOCUS ON SPECIALTY

EBV

PARVO

TOXO

BKV

CMV

VZV

ONCO HEMATOLOGY MYELO NEOPLL

ALL A LL

APL

SYSTEM

AML CML

LIAISON XL LAS CONFIGURATION

AN IMPORTANT R&D PIPELINE TO ADDRESS OPPORTUNITIES AND ENFORCE OUR RECOGNITION AS THE DIAGNOSTIC SPECIALIST

MARKETS AND SALES Chen Even

Senior Corporate VP Commercial Operations

DIASORIN IN THE 造 7BN IMMUNOASSAYS SEGMENT

OUT OF A WW IVD MARKET OF 造 33BN, DIASORIN MAIN FOCUS IS IMMUNOASSAY

IMMUNO ASSAYS

OUT OF A WW IMMUNOASSAY MARKET OF 造 7BN, DIASORIN MAIN CLINICAL AREAS OF INTEREST ARE: INFECTIOUS DISEASE

造 7BN

DRUG MONITORING OTHER GI STOOL TESTING 250 300 ONCOLOGY ALLERGY & ENDOCRINOLOGY 400 AUTOIMMUNITY

450

1,800

HEPATITIS AND RETROVIRUSES GI STOOL TESTING

BONE & MINERAL

ONCOLOGY AND ENDOCRINOLOGY BONE AND MINERAL

650 1,400

850 INFECTIOUS DISEASE

HEPATITIS AND RETROVIRUSES

900 CARDIAC MARKERS

DIASORIN AS A PURE PLAYER IN IMMUNOASSAY FOCUSING ON SPECIFIC AREAS

INFECTIOUS DISEASE (ex Heps & Retrovirus) MARKET

MARKET PLAYERS

WW: ¤ 850MLN TRENDS ID growing WW following demographics at 3-5% in the US and LatAm and >10% in China PRICING Price pressure due increasing competition

LATAM

150

NORTH AMERICA

250

200

to

APAC

250

MARKET SHARE DIASORIN: ABBOTT: BIOMÉRIEUX: SIEMENS: ROCHE: OTHERS:

SIEMENS 10% 25% 15% 10% 10% 30%

30%

10%

OTHERS

10%

ROCHE

25%

10% DIASORIN

15% A ABBOTT

BIOMERI BIOMERIEUX RIEUX RIE EUROPE

DIASORIN PURPOSE AND STRATEGY ¤ 60-70MLN ADDITIONAL REVENUES

STRATEGY: NEW SYSTEM LIAISON XL FRONT LINE ANALYZER AND LAS VERSION TO: • ACCESS MID-LARGE CLINICAL LABS • ACCELERATE PLATE CONVERSION

EU

USA AND LATAM Increased penetration with >10-15% MKT Share

• CONSOLIDATE ID BROAD ID MENU WITH HOOKS: • PARVOVIRUS • MMRV PANEL IN THE US • MYCOPLASMA

16%

Leadership reinforced with >30% MKT Share

CHINA Torch leadership on CLIA Platform

14% MARKET SHARE %

PURPOSE:

DIASORIN POSITIONING

12%

75%

G

WT RO

H

10% 8% 6%

10%

15%

4% 2% 0% 2011E

2015E Market Growth estimated at 5% CAGR

DIASORIN TO REINFORCE ITS ID LEADERSHIP POSITION, LEVERAGING ON INSTALLED BASE

HEPATITIS & RETROVIRUS MARKET WW: 造 1.5BN WW ex US, 造 750MLN

MARKET PLAYERS LATAM MARKET SHARE

USA ex

JAPAN:

TRENDS Growing volumes due to demographics, patients access to testing and urbanization in emerging markets PRICING Price erosion for HCV due to patent expiration

500

450

EUROPE EUROP PE P E

200

350

DIASORIN: ABBOTT: A SIEMENS: ROCHE: J&J: OTHERS:

5% 40% 15% 15% 15% 10%

DIASORIN

ROCHE

LEVERAGE THE MUREX BRAND

15%

1 15%

14% 12% MARKET SHARE %

LARGE INSTALLED BASE IN KEY EU MARKETS (>2,000) IN CLINICAL LABS

40%

J&J

DIASORIN POSITIONING

STRATEGY: LEVERAGE ON ID

FULL MENU: INCLUDING HCV, HBV, HIV, HTLV, SYPHILIS, AND CHAGAS ON LIAISON XL

10%

SIEMENS S

造 40-50MLN ADDITIONAL REVENUES

NEW SYSTEM: LIAISON XL FRONT LINE ANALYZER, TO ACCESS MID-LARGE LABS SEGMENT

5%

15%

APAC

DIASORIN PURPOSE AND STRATEGY PURPOSE:

ABBOTT

OTHERS

>55

10%

%

T OW R G

H

8% 6%

5%

4%

8%

8% 12%

2% 0%

DIFFERENTIATION: HBsAg WITH ENHANCED DETECTION OF MUTANTS ON LIAISON XL

DIASORIN AS A RELIABLE ALTERNATIVE TO THE MARKET LEADER

2011E 2011 01111E E

2015E 20 2015 015 015 5 5E Market Growth estimated at 2% CAGR

TOT MKT T

TOT MKT ex US, EX JAPAN

GI STOOL TESTING MARKET WW: ~ 造 300MLN EUROPE: 造 90MLN TRENDS

CAGR at +10-15% Increasing incidence of C. Difficile (hospital acquired infections) Low penetrated H. Pylori prevalence (Stomach Ulcers)

MARKET PLAYERS EUROPE

ROW

90 60

MERIDIAN

MARKET SHARE MERIDIAN:

30%

30%

OTHER SMALL-MEDIUM PLAYERS: 70%

150

Market size not attractive to big IVD players

70%

PRICING

Premium prices

OTHERS

USA

PURPOSE: 造 15-20MLN ADDITIONAL REVENUES STRATEGY: FIRST TO OFFER A GI STOOL PANEL ON A FULLY AUTOMATED PLATFORM USING MERIDIAN TECHNOLOGY LEVERAGE ON DIASORIN ID BUSINESS AGREEMENT WITH MERIDIAN TO CO-DEVELOP HIGH QUALITY STOOL PANEL TO BE MARKETED WW ex US MENU AVAILABLE ON LIAISON AND LIAISON XL TO GROW AND ANCHOR THE ID BUSINESS

DIASORIN POSITIONING DIASORIN WW MKT SHARE IN 2015 EXPECTED ~ 4%

4.0% 3.5% MARKET SHARE %

DIASORIN PURPOSE AND STRATEGY

3.0% 2.5% 2.0% 1.5%

0%

0.5% 0% 2011E

LEVERAGE ON ID BUSINESS

DIASORIN PIONEERING GI STOOL TESTING AUTOMATION

4%

1.0%

2015E Market Growth estimated at 12% CAGR

ONCOLOGY / ENDOCRINOLOGY MARKET

MARKET PLAYERS EUROPE

APAC

350

ID increase in volume due to higher prevalence, population ageing and promotion of urban lifestyle

700 250 2 50

PRICING

DIASORIN: ROCHE: SIEMENS: ABBOTT: OTHERS:

OTHERS

18%

> 2% 35% 25% 20% ~ 18%

ROCHE

35%

2% 20% % 25%

500

Low and stable in high routine Specialties high priced

MARKET SHARE

A LA ATAM LATAM

NORTH O AMERICA

DIASORIN PURPOSE AND STRATEGY PURPOSE:

造 30-40MLN ADDITIONAL REVENUES

STRATEGY:

NEW SYSTEM LIAISON XL FRONT LINE ANALYZER AND LAS VERSION ALLOWING TO ENTER IN MID-LARGE SIZE LABS FULL MENU AVAILABLE ENDO SPECIALTIES, SUCH AS RENIN AND ALDOSTERONE (HYPERTENSION) TO REINFORCE SPECIALIST REPUTATION TO DRIVE AND ANCHOR PLACEMENTS

SIEMENS DIASORIN ABBOTT A O

DIASORIN POSITIONING DIASORIN DOUBLING REVENUE WITHIN 2015

~

4.0%

2X

3.5% MARKET SHARE %

WW: 造 1.8BN TRENDS

US MENU EXPANSION: TO ANCHOR PLACEMENTS AND FORTIFY VITAMIN D POSITION

3.0% 2.5% 2.0% 1.5%

2.5%

4%

1.0% 0.5% 0% 2011E

2015E Market Growth flat

DIASORIN TO EXPLOIT ITS LARGE ONCOLOGY AND ENDO MENU WITH LIAISON XL

NUCLEIC ACID TESTING (NAT) MARKET WW: ¤ 3.4BN

LATAM

APAC

TRENDS

Annual increase: • Oncology: • Viral infection:

MARKET PLAYERS

450 250

+17% +34% +12%

1,500

PRICING

Decrease 10% due to: • New competitors • New technologies • Expiration of IP

1,200

MARKET SHARE ROCHE: QIAGEN: ABBOTT: G GEN-PROBE: SIE SIEMENS: OTHERS :

25% 15% 10% 9% 9% 32%

SIEMENS MENS GEN PROBE 9%

9% ABBOTT

15%

EUROPE

DIASORIN PURPOSE AND STRATEGY PURPOSE: ¤ 15-20MLN ADDITIONAL REVENUES STRATEGY: NEW NAT COST EFFECTIVE PRODUCT LINE USING LAMP TECHNOLOGY LEVERAGE ON THE LIAISON ID INSTALLED BASE (OVER 2,000) WITH COMPLIMENTARY ID NAT ASSAYS: LAUNCH 7 NAT ID TESTS IN 2012 LAUNCH A LAMP ANALYZER (LIAISON IAM) AND AN AUTOMATED EXTRACTOR WITHIN 2012 ENTER INTO THE ONCO-HEMATOLOGY TESTING MARKET WITH FULL TESTING MENU. LAUNCH 2 TESTS IN 2013

DIASORIN ADDRESSING A NEW MARKET

32%

10%

QIAGEN USA

OTHERS

25%

ROCHE

GEOGRAPHICAL EXPANSION BRAZIL CHINA ISRAEL MEXICO

AUSTRIA CZECH REP. IRELAND PORTUGAL

CANADA

AUSTRALIA NETHERLANDS SOUTH AFRICA

INDIA PURPOSE: penetrate a fast growing market STRATEGY: JV with local distributors

JAPAN PURPOSE: penetrate the richest IVD market STRATEGY: local distributor support or acquisition

2005-2007

2008

FURTHER GEOGRAPHICAL EXPANSION

2009

2010-2011

2012-2015

LIAISON XL, THE NEW FRONT LINE ANALYZER HIGH THROUGHPUT 180 TESTS/HOUR

FULL LSN MENU + HIV AND HCV

UP TO 25 REAGENTS ON BOARD

AVAILABLE TO CONNECT WITH LAS

CONSUMABLES LOADING

TOUCH SCREEN VIDEO

STARTER REAGENTS

REAGENTS

SAMPLES LOADING

MICROPARTICLES SUSPENDING AREA

CABINET

A COMPACT AND EFFICIENT DESIGN, WITH FEATURES ENHANCING DIASORIN VALUE PROPOSITION TO THE LABS

FROM LIAISON TO LIAISON XL 240 MAJOR COMPETITORS ARCHITECT 2000

200

CENTAUR XP UNICELDXI 600 VITROS 3600

THROUGHPUT/H

160

COBAS E

120

MAJOR COMPETITORS

80

CENTAUR CP ARCHITECT 1000 ACCESS II

40

0 5

10

15

20

25

30

REAGENT CHANNELS FROM LIAISON, BENCH TOP SPECIALTY MARKET ANALYZER TO LIAISON XL, FRONT LINE ANALYZER

35

40

LIAISON XL: COMPETITIVE ENVIRONMENT DIASORIN

ROCHE COBAS E

BECKMAN COULTER DXI 600

ABBOTT ARCHITECT 2000

SIEMENS CENTAUR XP

ORTHO VITROS 3600

THROUGHPUT

120

180

170

200

200

240

180

TOTAL MENU

92

94

73

57

50

60

50

MENU OF “SPECIALTIES”

++++

++++

++

+

+

+

+

TECHNOLOGY

CLIA

CLIA

ECLIA

CLIA

CMIA

CLIA

CLIA

++

+++

++

+++

+++

+++

++

> 4,000

<100

6,000

500

>10,000

5,000

500

B

F

F

F

F

F

F

LEVEL OF AUTOMATION

INSTALLED BASE

BENCH TOP / FLOOR

LIAISON XL: SUPERIOR CONTENT AND BREATH OF MENU

VITAMIN D Carlo Rosa

Chief Executive Officer

WORLDWIDE VITAMIN D MARKET: 2007-2011E 100.0 90.0 80.0

Million Tests

70.0

2

60.0

700

20

10

6 : +7 R G CA

CA 10 0 2 0720

50.0

GR

.7 %

:

.8 +78

20

20 07-

11E

200

%

7

6 : +5 R G CA

11 -20

EC

.3%

2 : +6 R AG

40.0 30.0 20.0 10.0 0 2007 00 07 WW market tests

2008 20 008 00 08 DiaSorin tests

AN IMPRESSIVE DEMAND GROWTH OVERTIME

2009 20 009 00 09

2010 20 010 010

2011E 20 011E 01

.1 %

17 173.5

MKT TESTS

79.4

94.9

113.4

132.9

125.3

147.4

149.8

150

133.5

DS TESTS

155.6

200

177.1 17 7

VITAMIN D PENETRATION

0.1

0.2

1.0

4.1

4.5

4.6

1.2

13.1

6.8

14.8

14.3

16.9

10.7

23.6

16.8

23.9

17.0

23.7

50

35.1

40.5

64.8

TESTS/1000 INHAB

100

0 ISRAEL

FRANCE

BELGIUM USA

AUSTRALIA

DENMARK

CANADA GERMANY NETHERLANDS

ITALY SPAIN

UK

CZECH REPUBLIC

PORTUGAL BRAZIL

JAPAN MEXICO

CHINA

VITAMIN D EXCEPTIONAL GROWTH TREND DUE TO: • CLINICAL EVIDENCE DISCOVERY • CHEAP SUPPLEMENTATION AVAILABILITY IN SEVERAL COUNTRIES • MEDIA COVERAGE ON VIT D EFFECTIVENESS

DIASORIN PRESENT IN BOTH PENETRATED/UNDERPENETRATED MARKETS WITH A MKT SHARE BETWEEN 50% AND 90% STILL LARGE OPPORTUNITY IN UNDERPENETRATED OR UNTOUCHED MARKETS

PRODUCT CYCLE OF VITAMIN D ADOPTION PRE - MKT PHASE

INTRODUCTION

GROWTH

MATURITY

DECLINE

USA

BELGIUM AUSTRALIAA

SALES

ISRAEL GERMANY

DENMARK

FRANCE

NETHERLANDS BRAZIL CANADA SPAIN ITALY

UK

MEXICO CZECH REPUBLIC PORTUGAL JAPAN

CHINA*

TIME *CALCULATED ON 100 MLN POPULATION ACCESSING HEALTHCARE

STILL LARGE OPPORTUNITY IN EARLY PHASE PRODUCT LIFE CYCLE MARKETS

# TESTS / 1% POPULATION PENETRATION

PRESCRIPTIONS AND POTENTIAL APPLICATIONS INTERNAL MEDICINE HOSPITAL AND HSP LABOUR

16% GENERAL PRACTICE

25%

6% 4%

OBSTETRIC & GYNEC. ENDOCRINOLOGY

4% 4% 2% 2%

30% 5%

MULTI SPECIALTY PRACTICE NEPHROLOGY

2%

GPS AND INTERNISTS ACCOUNT FOR 61% OF TOTAL TESTING PRESCRIPTIONS

REUMATOLOGY PEDIATRICS

FAMILY PRACTICE MAIN CURRENT APPLICATIONS

OTHERS

COMPANY DATA

FUTURE POTENTIAL APPLICATIONS

RATIONALE

DIABETES

INVERSE CORRELATION BETWEEN 25 OH VITAMIN D LEVELS AND BLOOD PRESSURE

HYPERTENSION

INVERSE CORRELATION BETWEEN VITAMIN D LEVELS AND GLUCOSE LEVELS

AUTOIMMUNITY

LOW VITAMIN D LEVELS ASSOCIATED WITH PREVALENCE AND PROGRESSION OF AUTOIMMUNE DISEASES (e.g. MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS)

ENDOCRINOLOGY

THE ENDOCRINE SOCIETY IDENTIFIED CANDIDATES FOR SCREENING USING VITAMIN D BLOOD LEVEL MEASUREMENTS

BONE DISORDERS

CURRENT EVIDENCE ON VIT D TESTING NEED AND FURTHER POTENTIAL APPLICATIONS BOOSTING FUTURE PRESCRIPTIONS

CONSOLIDATED VITAMIN D MARKETS US: VITAMIN D MARKET

21.0%

65 MLN TESTS

• 40% (125MLN) of the US population is Vitamin D deficient* or insufficient, but less then half is tested • Vitamin D tests/year can grow from 53MLN (2011E) to ~ 65MLN in the next 4 years, maturing to ~ 20% market penetration (~ 5% 2011-2015E CAGR) • Pricing: declining

MKT PENETRATION%

20.5% 20.0% 19.5% 19.0% 18.5% 18.0% 17.5%

53 MLN TESTS

20%

17.0% 16.5%

17%

16.0% 2011E

* US Census Bureau Data

EEUROPE: UROPPEE: V VITAMIN ITA AM MIN D MARKET MARK M ARKEETT

2015E

12%

• Vitamin D in european markets can double, from 20MLN (2011E) to ~ 40MLN in the next 4 years (10% penetration); (~ 19% 2011-2015E CAGR).

Still, only 1/4 of Vitamin D deficient will be tested

MKT PENETRATION%

40 MLN TESTS • 40% (150MLN) of Europeans are Vitamin D deficient or insufficient, but less than 5% are tested

10% 8% 6%

20 MLN TESTS

10%

4% 2%

• Pricing: declining

5%

0% 2011E

VITAMIN D IN US AND EUROPE: MARKETS THAT DIASORIN WILL CONTINUE TO PLAY

2015E

EMERGING VITAMIN D MARKETS CHINA: VITAMIN D MARKET

6%

• DiaSorin as the only provider on the chinese market with CLIA test just approved • Pricing: increasing

MKT PENETRATION%

5 MLN TESTS • Huge potential: unexplored market

5% 4% 3%

5%

2% 1% 0%

0% 2011E

BRAZIL: VITAMIN D MARKET

• US like market: increased awareness of Vitamin D benefits in Bone Diseases • Pricing: stabilizing

MKT PENETRATION%

• US like market: fast growing demand driven by big reference labs marketing activities

7%

2015E

12 MLN TESTS

6% 5% 4%

6%

3% 2%

1 MLN TESTS 1% 0%

0.5% 2011E

VITAMIN D IN EMERGING MARKETS: A HUGE OPPORTUNITY THAT DIASORIN IS READY TO PLAY

2015E

VITAMIN D IN JAPAN JAPAN VITAMIN D MARKET In Japan, Calcium and Vitamin D deficiency is more prevalent than in the US and Europe (Calcium and Vitamin D in Osteoporosis, Takuo Fajita, et al. Journal of Bone and Mineral metabolism, Japan Volume 9, N°2, August 1991)

Large Japanese Class A evidence Trial demonstrates low Vitamin D levels are associated with more bone fractures (effect of alendronate plus alfacalcidol in osteoporosis patients with high risk of fractures, Hajime Orimo et al. Current Medical Research & Opinion, vol 27, N°6, 2011)

OSTEOPOROSIS

DIASORIN STRATEGY Registration for pediatric indication and osteoporosis

13 MILLION CASES • Treatment given only in advanced disease

2.4MLN tests initially; potential to double in 3 to 5 years

• Rare use of estrogenic replacement therapy (culture) • Common use of Vitamin D derivatives and Calcium

JAPAN: POTENTIAL VITAMIN D MARKET

(Clinical Guidelines for treatment of osteoporosis in Japan, T. Fujita. Calcified Tissue International, Volume 59, Supplement 1, 1996)

• Increased skin pigmentation • Diet low in Vitamin D and low exposure to sunlight

5 MLN TESTS MKT PENETRATION%

PEDIATRICS

6.0% 5.0% 4.0% 3.0%

~ 4%

2.0% 1.0%

0%

0% 2011E

VITAMIN D IN JAPAN: AN UNTOUCHED OPPORTUNITY THAT DIASORIN IS READY TO PLAY

2015E

VITAMIN D MARKET GROWTH FORECAST 160.0 140.0 2 01

1E-

5E 2 01

MILLION TESTS

120.0 2 01

100.0

1E-

CA

4 : +1 GR

5E 2 01

CA

.4%

0 : +1 GR

.0 %

80.0 60.0 40.0 20.0 0 2011E 201 011E 01 1 WW market tests

2015E DiaSorin tests

DIASORIN AIMS TO MAINTAIN A SIGNIFICANT GROWTH, LEVERAGING ON ITS UNDISPUTED LEADERSHIP IN THE VITAMIN D MARKET

HUMAN CAPITAL Stefano Ronchi

Senior Corporate VP Human Resources

DIASORIN IDENTIFICATION

IDENTIFICATION IN LAST 10 YEARS

HOW WE DID IT

SINCE 2000 THE HISTORY OF THE COMPANY SAYS THAT DIASORIN IS

GLOBAL PLAYER FOCUSED ON: MISSION CUSTOMERS INNOVATION AND CONTENT (RECOGNIZED BRAND)

PEOPLE FOR DIASORIN: THE KEY FOCUS

COMPANY VISION STRATEGY & EXECUTION

“LINKED TO THE KNOWLEDGE” THE VALUE OF OUR PEOPLE

LEADERSHIP

A STORY OF GROWTH & VALUE

TECHNICAL KNOWLEDGE

RESULTS CAN BE ACHIEVED WITH FULL COMMITMENT OF OUR PEOPLE TO COMPANY AND CUSTOMERS

DIASORIN PEOPLE MAP AGE 20%

EDUCATION Biology B

17%

19%

Chemistry C Biochemistry B

39%

5%

Technical Degrees: 40%

Engineering E Economics: E 7%

30%

9%

33%

Other O graduates: 14% Technical High School: 39%

7% 14% 7% WORLDWIDE EMPLOYEES 2007-2010 <30 years

30-40 yearss

40-50 yearss

>50 years

SERVICE IN DIASORIN

+56%

POSITIONS 15%

27% 39%

50%

18%

35% 16%

0-3 years

3-5 years

5-10 years

>10 years

Technical

Commercial

WORLDWIDE EMPLOYEES’ GROWTH LINKED TO THE FAST GROWING EXPANSION OF THE BUSINESS

G&A

INVESTMENT IN HUMAN CAPITAL

NUMBERS ON 2007-2010

LEADERSHIP “TOP 20” MANAGEMENT POSITIONS:

35%

45%

MANAGERS PROMOTED

NEW MANAGERS

43 NEW ENTRIES IN 20 DIFFERENT COUNTRIES AS “KEY MANAGERS”

INVESTMENT ON OUR

TALENTS ACCOUNTABILITY OF THE TOP MANAGEMENT IN MANAGING THE “KEY-PEOPLE” THROUGH: CAREER DEVELOPMENT INTERNATIONAL MOBILITY RETENTION PLANS COMPENSATION REWARDING RESULTS

MARKET PROVENANCE: DIAGNOSTIC MARKET FOR

BUSINESS & MANAGERIAL ROLES BIGGER INTERNATIONAL CORPORATIONS FOR

CORPORATE & CROSS FUNCTIONAL ROLES THE KEY-ELEMENTS ON WHICH DIASORIN HAS BUILT ITS SUCCESS ARE THE VALUE AND QUALITY OF ITS HUMAN CAPITAL

DIASORIN MANAGEMENT STYLE COMPETENCE

SELF-CRITICISM/INSURANCE OF STRENGTHS ENERGY

PASSION

IMPLEMENTATION /ACTION

DEDICATION

PRAGMATISM

ABILITY TO TAKE DECISIONS

IDENTIFICATION WITH THE COMPANY ATTENTION TO DETAILS

HUMAN CAPITAL: VALUE OF INTANGIBLE ASSETS

DIASORIN LEADERSHIP: 2012-2015 MODEL REFLECTS VALUES AND TRAITS OF A TRUSTWORTHY MANAGEMENT DEFINES A COMMON LANGUAGE ON THE WAY “TO BE A LEADER” INCREASES EXCELLENCE MANAGEMENT GOING FORWARD

WE IDENTIFY OURSELVES IN THESE VALUES THE MARKET CAN MATERIALLY VALUE US ON THESE TRAITS HR SUPPORTS THE ENHANCEMENT OF THE QUALITY OF ITS LEADERS

DIASORIN: RIDING A NEW BUSINESS WAVE DIASORIN LEADERSHIP MODEL, A WELL-BALANCED MIX OF ENTREPRENEURIAL SPIRIT AND MANAGERIAL SKILLS

IDENTIFICATION WITH THE COMPANY ORIENTATION ENNNTT TO RE RES RESULTS EES

INNOVATION AND CHANGE DRIVER

ENERGY, GYYY, DRIVE AND PRO-ACTIVITY -AAACC

QUALITY

ACCOUNTABILITY

CARE FOR CUSTOMERS

INTEGRITY

PEOPLE INSPIRING

ENTREPRENEURIAL SPIRIT

MANAGERIAL SKILLS

HR SUPPORTS THE FUTURE GOALS OF THE COMPANY

2012-2015: RIDING A NEW BUSINESS WAVE Andrea Senaldi Senior Corporate VP and Chief Financial Officer Carlo Rosa Chief Executive Officer

HISTORICAL FINANCIALS 造/MLN

FY 2010

FY 2009

2010 VS. 2009

FY 2008

FY 2007

SALES

404.5

304.1

244.6

202.3

EBITDA %

167.1 41.3%

123.6 40.7%

+ 33.0% + 35.2%

85.6 35.0%

64.0 31.6%

EBIT %

145.5 36.0%

106.4 35.0%

+ 36.8%

70.8 28.9%

50.1 24.7%

NET RESULT %

90.4 22.4%

70.0 23.0%

+ 29.1%

37.5 15.3%

25.2 12.5% As reported

YoY GROWTH +100%

+87.0% + 75%

CAGR 2007-2010

+26.0% +48.5%

+50.3% CAGR 2007-2010

+36.8%

+50%

+41.4% +44.4% +25%

+33.8% +20.9%

+24.3%

+35.2% +33.0% +29.1%

+37.7% +42.7%

EBIT

CAGR 2007-2010

+53.1% 2009

EBITDA

CAGR 2007-2010

+0%

2008

SALES

2010

STRONG RESULTS AND HIGH PROFITABILITY DISREGARDING WORLDWIDE ECONOMIC SITUATION

NET RESULT

2010 KEY NUMBERS 2010 SALES BREAKDOWN

SALES BY GEOGRAPHY IN €/MLN

304.1

19.6%

+17.0

+6.8 LATAM

APAC

EUROPE & AFRICA

5.2% 9.3%

RIA

+10.3

+43.2

+23.1

404.5

MUREX NORTH AMERICA

65.9%

ELISA

LIASON

INSTRUMENTS + OTHER

FY 2009

2010 COSTS BREAKDOWN

FY 2010 COSTS COMPONENTS IN €/MLN

3.2%

+29.3

16.1%

198.7

7.5%

+12.9

+3.3 R&D

+9.3 SG&A

+5.5

259.0

OTHER COSTS

S&M COGS

46.2%

27.0%

COGS

S&M

R&D

SG&A

OTHER COSTS

FY 2009

FAST SALES GROWTH PACE SUPPORTED BY A WELL MANAGED COST STRUCTURE

FY 2010

HISTORICAL BALANCE SHEET AND CASH FLOW FY 2010

FY 2009

FY 2008

FY 2007

TANGIBLE ASSETS

57.6

42.0

35.4

33.9

INTANGIBLE ASSETS

126.9

96.6

93.3

65.4

OTHER NON-CURRENT ASSETS

20.2

19.6

10.1

9.2

NET WORKING CAPITAL

106.4

74.5

57.7

46.2

OTHER NON-CURRENT LIABILITIES

(28.2)

(25.3)

(22.9)

(22.3)

NET CAPITAL EMPLOYED

282.9

206.7

173.9

s132.4

33.1

11.2

(19.8)

(12.1)

315.9

217.9

154.1

120.3

NET CHANGE IN CASH AND CASH EQUIVALENTS

+14.507

+31.095

+8.423

-0.351

CASH AND EQUIVALENTS AT THE END OF THE PERIOD

62.392

47.885

16.790

8.367

¤/MLN

NET FINANCIAL POSITION TOTAL SHAREHOLDERS’ EQUITY

50

SOLID RESULTS AND VALUE GENERATION DISTINGUISHING OUR COMPANY SINCE IPO

INSTALLED BASE AND REVENUE PER BOX 80.6K 0 –2 4 00 % 2 GR >10 CA

10

3,912 3,641 2,975

LIAISON REVENUE PER BOX

2,510 44.6K

0 2,070

990

20 – 4 00 % 2 G R > 24 CA

10

LIAISON INSTALLED BASE

2004

2007

2008

4,000 INSTALLED MACHINES TARGET ALREADY ACHIEVED

2009

2010

H1 11

H1 2011 RESULTS H1 2011

H1 2010

H1’11 VS. H1’10

227.1

187.2

+21.3%

DESPITE NEGATIVE FX IMPACT ON SALES

EBITDA %

101.4 44.7%

80.4 42.9%

+26.2%

IMPROVED TECHNOLOGY MIX

EBIT %

88.4 38.9%

70.9 37.9%

+ 24.6%

NET RESULT %

56.4 24.8%

43.0 23.0%

+31.1%

06/30/2011

12/31/2010

57.3

57.6

122.7

126.9

Operating cash flow: ¤ 49.5MLN, before

21.2

20.2

Capex of ¤ 11.9MLN (¤ 40.4MLN in H1’10,

125.0

106.4

(30.6)

(28.2)

295.6

282.9

22.7

33.1

318.3

315.9

H1 2011

H1 2010

-16.938(1)

-23.084

¤/MLN

SALES

TANGIBLE ASSETS INTANGIBLE ASSETS OTHER NON-CURRENT ASSETS NET WORKING CAPITAL OTHER NON-CURRENT LIABILITIES NET CAPITAL EMPLOYED NET FINANCIAL POSITION TOTAL SHAREHOLDERS’ EQUITY

NET CHANGE IN CASH AND CASH EQUIVALENTS CASH AND EQUIVALENTS AT THE END OF THE PERIOD

45.454

PROFITABILITY IMPROVEMENT

CLIA revenues: 73.2% (+450bps vs. H1’10) Higher incidence of high margins tests sales Lower incidence of operating expenses

24.801

SOLID FINANCIAL STRUCTURE

before Capex of ¤ 12.5MLN)

FINANCIAL POSITION AT 06/30/11 +¤ 22.7MLN

(1)

Decrease of ¤ 16.9MLN due to: Share buyback plan Australia distr. Rights + Murex Dividends payment

H1 2011 RESULTS CONFIRMING A STRONG YEAR, DESPITE THE WORLDWIDE ECONOMIC SITUATION

-25.1 -3.2 -22.0

H1’11 KEY NUMBERS H1 2011 SALES BREAK DOWN

SALES BY GEOGRAPHY IN €/MLN

19.1%

187.2

+9.0

+5.4 LATAM

4.2%

+7.1 APAC

+1.6

+16.8

227.1

MUREX

NORTH AMERICA

EUROPE & AFRICA

9.3% 67.4%

RIA

ELISA

LIASON

INSTRUMENTS + OTHER

H1 2010

H1 2011 COSTS BREAKDOWN

H1 2011 COSTS COMPONENTS IN €/MLN

2.7% 15.9%

116.3 7.7%

+10.2

+6.4

+2.1 R&D

+3.8

138.8

SG&A

S&M COGS

45.3% 28.4%

COGS

S&M

R&D

SG&A

OTHER COSTS

H1 2010

FAST SALES GROWTH PACE SUPPORTED BY A WELL MANAGED COST STRUCTURE

H1 2011

2011 EXPECTED RESULTS GROWTH ¤/MLN

FY 2011 E

FY 2010

AS REPORTED

CER*

SALES

~

450

405

~

11%

~

13%

EBITDA

~

200

167

~

20%

~

23%

MARGIN

~

44%

41%

* FX change as of 2010

CHALLENGING AND TOUGH ECONOMIC ENVIRONMENT, BUT: • STILL DOUBLE DIGIT GROWTH IN SALES • FURTHER IMPROVEMENT IN PROFITABILITY

HEALTHY RESULTS EXPECTED, NOTWITHSTANDING WEAKNESS IN ECONOMIC ENVIRONMENT

STOCK PRICE PERFORMANCE 350 300 250 +120.1%

200 150 -8.6%

100 50

DiaSorin

1 19

9/

/2 19 7/

/2

01

01

1

1 01

1 5/

19

/2

01

1

/2

/2

19 3/

19 1/

9/

20

01 /1 11

/2 19 9/

01

10

0

0 01

0

/2

/2

19 7/

01

19

/2 19

5/

/2 3/

19 1/

01

0

0 01

09

9

20 9/ /1

11

9/

19

/2 19 7/

/2

00

00

9

9 00

9

/2 19

5/

/2 19

3/

1/

19

/2

20

00

00

9

08

8 9/ /1 11

19 9/

/2 19 7/

Italy FTSE MIB

/2

00

00

8

8 00

8

/2 19

5/

/2

19 3/

19 1/

/2

00

00

8

08 20 9/

/1 11

/2 19 9/

7/

19

/2

00

00

7

7

-66.5%

Competitors benchmark

Competitors Benchmark weighted for Mkt Cap in 造/mln includes: BioMerieux, Qiagen, Gen-Probe, Alere, Cepheid, Immucor, Myriad Genetics, Tecan Group, Meridian Bioscience, Abaxis, Stratec Biomedical, Quidel, Axis-Shield, Beckman Coulter, Becton Dickinson

DIASORIN STOCK PRICE PERFORMANCE SINCE IPO BEATING ITALY FTSE MIB AND COMPETITORS BENCHMARK TREND

TARGET PRICES AND RATINGS STOCK CURRENTLY TRADING AT A HIGHER DISCOUNT VS. CONSENSUS ESTIMATES AND THE AVG. 12 MONTHS TP

8

7

7

7

7

8

9

9

9

10

11

11

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

13

# of Brokers

40

38 36 34

32

30 28

26 24

Sep´10 Oct

Buy + Overweight

Hold

Sell + Underweight

Price

Sep´11

Target Price Source: FactSet

POTENTIAL 12 MONTHS UPSIDE ON ANALYSTS ESTIMATES ˜ 33%

2012-2015 STRATEGY

BUSINESS PLAN REVENUES MAIN ASSUMPTIONS VITAMIN D SALES 2011-2015 CAGR

LIAISON SALES (EX VITAMIN D) 2011-2015 CAGR

MUREX SALES 2011-2015

NAT GENERATING BY 2015 €/MLN SALES

2.2%

21%

7%

15-20

FOCUSING AGAINST OTHER LARGE EIA SUPPLIERS (ORTHO CLINIC DIAGNOSTICS & BIO-RAD LABORATORIES)

WITH THE INITIAL INFECTIOUS DISEASE AND ONCOLOGY PANEL LAUNCHED BY END 2012

PRICE EROSION IN THE US AND EUROPE CAGR ~ 7%

LAUNCH OF BLOOD SCREENING PANEL

VOLUME CAGR: ~ +10%

LAUNCH OF STOOL PANEL IN 2012 [C. DIFFICILE IN Q4 2011]

LAUNCH OF VITAMIN D IN JAPAN BY Q4 2012

LAUNCH OF HYPERTENSION PANEL IN 2012 AND MARKET SHARE INCREASE IN INFECTIOUS DISEASE AND ONCOLOGY

DIASORIN: RIDING A NEW BUSINESS WAVE

BUSINESS PLAN MAIN MARGIN ASSUMPTIONS

GROSS MARGINS FLAT ON 2011: >70% PRESSURE IN VITAMIN D PRICES SCALE ECONOMIES IN MANUFACTURING PLANTS REDUCED ROYALTY RATES

OPERATING MARGINS: SUSTAINABLE THROUGHOUT THE PERIOD ADDITIONAL INVESTMENT COMPENSATED THROUGH OPERATING LEVERAGE

DIASORIN: RIDING A NEW BUSINESS WAVE

DIASORIN ADDITIONAL REVENUES BREAKDOWN MARKET VALUE ¤/MLN

INFECTIOUS DISEASE (EX HEPATITIS AND RETROVIRUSES)

WW

850

HEPATITIS AND RETROVIRUSES

WW 1,500 WW ex US Japan 750

WW DIASORIN MARKET SHARE

REVENUES POTENTIAL ¤/MLN

DIASORIN STRATEGY

2011E

2015E

10%

~ 15%

60-70

Liaison XL to: - access mid-large clinical labs - accelerate plate conversion - consolidate ID ID menu hooking: - Parvovirus - MMRV panel (USA) - Mycoplasma

5%

~ 8%

40-50

- Leverage on ID - Liaison XL - Full menu proposition - Menu differentiation - Large Installed base in Key markets - Murex Brand

and

ONCOLOGY AND ENDOCRINOLOGY

WW 1,800

2%

~ 4%

30-40

- Liaison XL - Full menu proposition - Specialties proposition - USA menu expansion - Hypertension

GI STOOL TESTING

WW 300 Europe ~ 100

-

~ 4%

15-20

- 1st offering GI stool panel on fully automated platform - Leverage on ID - Co-development of stool panel for WW market (ex US) - ID growth and anchorage with menu on Liaison + Liaison XL

NUCLEIC ACID TESTING (NAT)

WW 3,400

-

n.m.

15-20

- New NAT product line using LAMP - Leverage on installed base with complementary NAT assays - 2012 launch: - 7 NAT ID tests - LAMP analyzer (LIAISION IAM) - Automated Extractor - Stool collection device - New market penetration: Onco-Hematology (2 tests in 2013)

VITAMIN D

WW 270

55%

~ 45%

10-20

- Maintenance of Vit D market leadership - New markets penetration (e.g. Japan - Q4’12)

DIASORIN: RIDING A NEW BUSINESS WAVE

2012-2015 GUIDANCE FY 2011 E

¤/MLN

FY 2015 E

SALES

~

450

630-680

EBITDA

~

200

> 280

10% ~ E 01 5 2 – 1E 1 0 2 9% GR ~ A C E 01 5 2 – 1E 1 0 R2 G CA

2015 E

2011 E SALES

DIASORIN: RIDING A NEW BUSINESS WAVE

EBITDA

FUTURE M&A DIASORIN STRONG BALANCE SHEET AND CASH GENERATION ALLOW US TO LOOK FOR FUTURE ACQUISITIONS IN TERMS OF: CUMULATED FREE CASH FLOW @2015E: EBITDA FY 2015E:

CONTENTS

~ 600 > 280

TECHNOLOGIES PRODUCTS DEVELOPMENT OF NET DEBT AND EBITDA

NET DEBT / EBITDA RATIO 0.35x 0.25x 0.15x 0.05x (0.05x) (0.15x) (0.25x)

FY 2007

EBITDA

FY 2008

N Net Debt

FY 2009

FY 2010

FY 2007

FY 2008

Net Debt/EBITDA

DIASORIN CASH AS THE BASIS FOR FUTURE ACQUISITIONS AND AGREEMENTS

FY 2009

FY 2010

RIDING A NEW BUSINESS WAVE

VALUE

SUSTAINABLE GROWTH

INNOVATION QUALITY

COMMITMENT TO CLIENTS